Novel immunotherapy agent safe, shows promise against high-risk prostate cancers

A new drug, a monoclonal antibody known as enoblituzumab, is safe in men with aggressive prostate cancer and may induce clinical activity against cancer throughout the body, according to a phase 2 study led by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy. If confirmed in additional studies, enoblituzumab could become the first promising antibody-based immunotherapy agent against prostate cancer.

Model developed for predicting disease progression in hep B liver cirrhosis

For patients with hepatitis B virus (HBV) liver cirrhosis-acute decompensation (LC-AD), a model combining computed tomography (CT) quantified extracellular liver volume (ECVIC-liver) and chronic liver failure consortium-acute decompensation score (CLIF-C ADs) can predict the occurrence of acute-on-chronic liver failure (ACLF), according to a study published online March 29 in Insights into Imaging.

How the brain slows down when we focus our gaze

Changing between slow and fast integration of information, the brain can flexibly modulate the timescales on which it operates. This is the result of a new study by an international team of researchers, now published in the journal Nature Communications. Their analysis of experimental data from the visual cortex and their computer simulations also provide an explanation for how different timescales can arise and how they can change: the structure of the neural networks determines how fast or slow information is integrated.